SURVYR

BMY

Bristol-Myers Squibb Company
$61.68
+$2.85 (4.84%)Oct 20 close
Health CareS&P 500 CompareTechnicals
1M3M6M1Y2Y
-5%+12%+30%+47%+64%Oct 2025Oct 2026Apr 202652w high $68.6452w low $42.52
BMYSPY
Wall St. Highest PT $82.00 (+32.9%) Wall St. Avg PT $65.42 (+6.1%)
$41$52$63$74$84POC $57Hi $82Avg $65
Underwater Drawdown %Max DD -15.9%Current -8.5%
0.0%-15.9%
Relative Strength vs SPY+32.0% vs SPYOutperforming
+53%0%-53%
1W
+$5.01 (8.84%)
1M
−$0.73 (1.18%)
3M
+$1.37 (2.28%)
6M
+$3.55 (6.12%)
YTD
+$10.04 (19.44%)
1Y
+$19.95 (47.80%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
24 analysts · mean score 2.50
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$61.68
Average target$65.42
+$3.74 (+6.1%) upsideaverage target vs current price
CurrentAverageMedian
Low$41.00
Median$65.42
High$82.00
12-month Wall Street target range
Recent analyst rating changes · 8
Reiterated
2026-10-13 · Wells Fargo reiterated Equal-Weight on BMY
Reiterated
2026-10-08 · Cantor Fitzgerald reiterated Neutral on BMY
Reiterated
2026-10-07 · Morgan Stanley reiterated Underweight on BMY
Downgrade
2026-10-05 · Leerink Partners downgraded BMY from Outperform to Market Perform
Reiterated
2026-09-16 · Piper Sandler reiterated Overweight on BMY
Reiterated
2026-09-10 · HSBC reiterated Hold on BMY
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$126.0B
P/E (last 12 months)13.6
P/E (next 12 months, estimated)9.3
52-week range$42.52 – $68.64
Revenue growth (latest quarter vs a year ago)+5.7%
Dividend yield4.09%
Analyst consensusBuy (24)
Average analyst price target$65.42 (+6%)

What they do

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors.

Healthcare · Drug Manufacturers - General
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
73rd percentile in sector
B+
12-1 return: +40.0%
Percentile within its GICS sector across the S&P 1500.
Growth
33rd percentile in sector
C-
Revenue growth (YoY): +5.7%
Percentile within its GICS sector across the S&P 1500.
Value
89th percentile in sector
A
Forward E/P: 11.1% · EBITDA/EV: 12.1%
Percentile within its GICS sector across the S&P 1500.
Profitability
86th percentile in sector
A-
Profit margin: +18.9% · Return on equity: +46.6%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
ranked 53 of 499 · 12-month momentum 55.2%
 Momentum Blend
Not in the current book
 New Highs Growth
ranked 32 of 589 · 12-month momentum 58.6%
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

BMY earningsReports tomorrow
Next report · quarter Sep 2026
Thu Oct 29, 2026Before the open
EPS consensus$1.28 range $0.98–$1.87
Revenue consensus$12.7B 21 analysts
Last 4 quarters · EPS vs estimate
Jul 30, 2026$2.04est $1.60+27.7%Above estimates
Apr 30, 2026$1.58est $1.42+11.2%Above estimates
Feb 5, 2026$1.26est $1.20+4.6%Above estimates
Oct 30, 2025$1.63est $1.52+7.5%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-21 01:32:09 ET
24-1025-0225-0425-0725-1026-0226-0426-070.002.04
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$13.0B+5.7%
2026-03-31$11.5B–
2025-12-31$12.5B–
2025-09-30$12.2B–
2025-06-30$12.3B–

Recent dividends

2026-10-02: $0.630 · 2026-07-02: $0.630 · 2026-04-02: $0.630 · 2026-01-02: $0.630 · 2025-10-03: $0.620 · 2025-07-03: $0.620 · 2025-04-04: $0.620 · 2025-01-03: $0.620

News & catalysts

More news
Has Regeneron Stock Become A Different Bet?
Trefis · 15h ago
Bristol Myers Squibb’s Cancer Drug Just Doubled Survival Time Without Progression — Here’s Why It Matters
Nasdaq · Oct 27
Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue
Nasdaq · Oct 22
Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility
Nasdaq · Oct 22
Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?
Nasdaq · Oct 22
Rating changes
Reiterated
2026-10-13 · Wells Fargo reiterated Equal-Weight on BMY
Reiterated
2026-10-08 · Cantor Fitzgerald reiterated Neutral on BMY
Reiterated
2026-10-07 · Morgan Stanley reiterated Underweight on BMY
Downgrade
2026-10-05 · Leerink Partners downgraded BMY from Outperform to Market Perform
Reiterated
2026-09-16 · Piper Sandler reiterated Overweight on BMY
Reiterated
2026-09-10 · HSBC reiterated Hold on BMY

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-21 01:32:09 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026